*Colchicine & Spironolactone in Acute MI: No Significant Benefit 🚫* *🔑 Key Findings:* • *Colchicine*: No reduction in the composite primary outcome (cardiovascular death, recurrent MI, stroke, or unplanned revascularisation). • Results: 9.1% event rate in the colchicine group vs. 9.3% in the placebo group. • Hazard Ratio: 0.99 (95% CI, 0.85–1.16; P=0.93) • *Spironolactone*: No significant reduction in death from cardiovascular causes or new/worsening heart failure. • Results: 1.7 events/100 patient-years in spironolactone vs. 2.1 in placebo. • Hazard Ratio: 0.91 (95% CI, 0.69–1.21; P=0.51) 🩺 *Clinical Implication:* Routine use of colchicine and spironolactone post-MI does not improve outcomes. *🔗 Original Articles:* 📄 Colchicine: https://doi.org/10.1056/NEJMoa2405922 📄 Spironolactone: https://doi.org/10.1056/NEJMoa2405923 #medicalresearch @Updates_in_Medicine